Lead preclinical program

Buccal 5-MeO-DMT

Scientific approach

5-MeO-DMT has a rapid pharmacological profile and active research interest across neuropsychiatric conditions. AERASYN's preclinical program is designed to compare how buccal formulation may influence absorption, onset, exposure and dose consistency.

EXPOSURE PROFILE

Program profile

Current development context.

Review relevant intellectual property
Development stagePreclinical
Research contextNeuropsychiatric therapeutic research
Delivery routeBuccal
Primary evidence needsComparative PK, bioavailability, safety and tolerability
Relevant IPTherapeutic and delivery

Our Pipeline

Explore all four AERASYN programs.

Return to Pipeline